Duality Biotherapeutics, Inc. (HKG:9606)

Duality Biotherapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	1,209	1,131
Short-Term Investments	188.06	5.26
Cash & Short-Term Investments	1,397	1,136
Cash Growth	22.96%	-
Accounts Receivable	379.02	100.8
Other Receivables	70.44	32.55
Receivables	449.46	133.35
Restricted Cash	45.16	42.65
Other Current Assets	18.26	21.75
Total Current Assets	1,910	1,334
Property, Plant & Equipment	18.6	17.76
Other Intangible Assets	46.24	54.25
Other Long-Term Assets	115.56	94.01
Total Assets	2,090	1,500
Accounts Payable	670.91	234.81
Accrued Expenses	38.97	25.24
Current Portion of Leases	2.99	2.91
Current Income Taxes Payable	1.72	0.92
Current Unearned Revenue	90.26	156.13
Other Current Liabilities	3,067	2,141
Total Current Liabilities	3,872	2,561
Long-Term Leases	2.3	2.41
Long-Term Unearned Revenue	238.25	60.16
Total Liabilities	4,112	2,624
Common Stock	0.01	0.01
Retained Earnings	-2,161	-1,111
Comprehensive Income & Other	133.26	-19.2
Total Common Equity	-2,028	-1,130
Shareholders' Equity	-2,022	-1,124
Total Liabilities & Equity	2,090	1,500
Total Debt	5.29	5.32
Net Cash (Debt)	1,392	1,131
Net Cash Growth	23.07%	-
Net Cash Per Share	173.96	141.35
Filing Date Shares Outstanding	8	8
Total Common Shares Outstanding	8	8
Working Capital	-1,962	-1,227
Book Value Per Share	-253.46	-141.22
Tangible Book Value	-2,074	-1,184
Tangible Book Value Per Share	-259.24	-148.00
Machinery	10.74	7.61
Construction In Progress	0.55	0.19
Leasehold Improvements	6.92	6.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.